Phosphomannomutase 2 Deficiency
0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
GlycomineCA - San Carlos
2 programsNatural History Study Protocol in PMM2-CDG (CDG-Ia)N/A1 trial
GLM101PHASE_2_31 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
GlycomineGLM101
GlycomineNatural History Study Protocol in PMM2-CDG (CDG-Ia)
Clinical Trials (2)
Total enrollment: 170 patients across 2 trials
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
Start: Jul 2025Est. completion: Apr 202750 patients
Phase 2/3Active Not Recruiting
Natural History Study Protocol in PMM2-CDG (CDG-Ia)
Start: Jan 2018Est. completion: Mar 2026120 patients
N/AActive Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.